Immune 'hotness' and growth markers may sharpen lymphoma prognosis
NCT ID NCT07804173
First seen Sep 04, 2026 · Last updated Sep 04, 2026
Summary
This study examines tissue samples from 70 people with diffuse large B-cell lymphoma and other aggressive B-cell lymphomas. Researchers will measure immune cell infiltration, called tumor 'hotness', and the Ki-67 proliferation index using two scoring methods. The goal is to see if combining these markers creates a more accurate prognostic model than current approaches. The study does not test a new treatment; it analyzes existing biopsy samples to better understand which patients may have a more aggressive disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a more accurate way to predict outcomes in aggressive lymphomas, helping doctors tailor treatment intensity.
- What could go wrong
- This is a small, observational lab study, not a treatment trial. The findings may not change clinical practice without further validation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Blocks obtained from patients diagnosed as Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Patients diagnosed with Diffuse Large B Cell Lymphoma, not otherwise specified (DLBCL, NOS) and other aggressive large B-cell lymphomas, according to current WHO/ICC diagnostic principles. * Histopathological diagnosis obtained by excisional biopsy, core biopsy or adequate tissue biopsy. * Availability of FFPE tissue blocks with sufficient viable tumor for immunohistochemical (IHC) staining. * Diagnostic tissue obtained before the initiation of definitive systemic therapy. * Available minimum clinical data: age, sex, date of diagnosis, treatment status, and follow-up/survival status. * For survival analysis: cases with documented follow-up date or date of death/progression. Exclusion Criteria: * • Inadequate tissue, exhausted block or severe fixation/processing artifact preventing reliable IHC interpretation. * Extensive necrosis, crush artifact or decalcification artifact in the only available diagnostic tissue. * Relapse biopsy after chemotherapy without available pretreatment diagnostic tissue. * Primary Hodgkin lymphoma, indolent B-cell lymphoma without transformation, T-cell lymphoma or metastatic non-lymphoid malignancy. * Cases lacking essential clinical outcome data for prognostic analysis (except for descriptive staining analysis). * HIV-associated, post-transplant or primary CNS DLBCL may be excluded or analyzed separately due to distinct biology.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aggressive large B-cell lymphoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sohag university
Sohag, 82511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.